| Literature DB >> 32886678 |
Adela Ngwewondo1, Lucia Nkengazong1, Lum Abienwi Ambe1, Jean Thierry Ebogo1, Fabrice Medou Mba1, Hamadama Oumarou Goni1, Nyemb Nyunaï1, Marie Chantal Ngonde1,2, Jean-Louis Essame Oyono1.
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (COVID 19) has plagued the world with about 7,8 million confirmed cases and over 430,000 deaths as of June 13th, 2020. The knowledge, attitude, and practices (KAP) people hold towards this new disease could play a major role in the way they accept measures put in place to curb its spread and their willingness to seek and adhere to care. We sought to understand if: a) demographic variables of Cameroonian residents could influence KAP and symptomatology, and b) KAP could influence the risk of having COVID19.A cross-sectional KAP/symptomatology online survey was conducted between April 20 to May 20. All analyses were performed using SPSS version 23. Of all respondents (1006), 53.1% were female, 26.6% were students, 26.9% interacted face to face and 62.8% were residents in Yaoundé with a median age of 33. The overall high score was 84.19% for knowledge, 69% for attitude, and 60.8% for practice towards COVID 19. Age > 20 years was associated with a high knowledge of COVID 19. Women had lower practice scores compared to men (OR = 0.72; 95%CI 0.56-0.92). 41 respondents had ≥3 symptoms and only 9 (22.95%) of them had called 1510 (emergency number). There was no significant difference between KAP and symptomatology. The presence of ≥ 3 symptoms in 4% of respondents (with 56% of them having co-morbidities) supports the current trend in the number of confirmed cases (8681) in Cameroon. The continuous increase in the number of cases and the overall good KAP warrants further investigation to assess the effectiveness of the measures put in place to curb the spread of the disease. Sensitization is paramount to preclude negative health-seeking behaviors and encourage positive preventive and therapeutic practices, for fear of an increase in mortality.Entities:
Mesh:
Year: 2020 PMID: 32886678 PMCID: PMC7497983 DOI: 10.1371/journal.pntd.0008700
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Demographic characteristics of participants.
| Demographics/characteristics | Number of respondents | Percentage (%) |
|---|---|---|
| • | 472 | 46.9 |
| • | 534 | 53.1 |
| Age | ||
| • | 32 | 3.2 |
| • | 361 | 35.9 |
| • | 367 | 36.5 |
| • | 139 | 13.8 |
| • | 107 | 10.6 |
| • | 99 | 9.8 |
| • | 182 | 18.2 |
| • | 141 | 14 |
| • | 17 | 1.7 |
| • | 268 | 26.6 |
| • | 135 | 13.4 |
| • | 164 | 16.3 |
| • | 205 | 20.4 |
| • | 271 | 26.9 |
| • | 102 | 10.1 |
| • | 257 | 25.5 |
| • | 171 | 17.1 |
| • | 632 | 62.8 |
| • | 146 | 14.5 |
| • | 89 | 8.8 |
| • | 139 | 13.9 |
Source/ period of information on COVID 19.
| Month/Source of information | Mouth to mouth | Newspaper | Television | Websites | Total | |
|---|---|---|---|---|---|---|
| 25(6.0%) | 27(6.4%) | 246(58.7%) | 77(18.4%) | 44(10.5%) | 419 | |
| 14(5.1%) | 13(4.8%) | 141(51.6%) | 46(16.8%) | 59(21.6%) | 273 | |
| 19(11.2%) | 6(3.6%) | 84(49.7%) | 26(15.4%) | 34(20.1%) | 169 | |
| 28(19.3%) | 7(4.8%) | 77(53.1%) | 13(9.0%) | 20(13.8%) | 145 | |
| 86(8.5%) | 53(5.3%) | 548(54.5%) | 162(16.1%) | 157(15.6%) | 1006 | |
| 50(7.2%) | 34(4.9%) | 370(53.3%) | 123(17.7%) | 117(16.9%) | 694 | |
| 36(11.5%) | 19(6.1%) | 178(57.1%) | 39(12.5%) | 40(12.8% | 312 | |
| 86(8.5%) | 53(5.3%) | 548(54.5%) | 162(16.1%) | 157(15.6%) | 1006 | |
Knowledge, attitudes, and practices of COVID 19 among the 1006 respondents in Cameroon, n (%).
| Questions/ options | Yes (%) | No (%) |
|---|---|---|
| K1. Droplets when an infected person coughs, sneezes or speaks | 941 (94.3) | 5.7 (57) |
| K2. Kissing an infected person | 761 (75.6) | 245 (24.4) |
| K3. Handshake | 751 (74.7) | 255 (25.3) |
| K4. Touching a contaminated surface and then touching your eyes, nose or mouth | 888 (88.3) | 118 (11.7) |
| K5. Blood transfusion | 77 (7.7) | 929 (92.3) |
| K6. Sexual intercourse | 74(7.4) | 932 (92.6) |
| K7. Contaminated foodstuffs | 377 (37.5) | 629 (62.5) |
| Yes (%) | No (%) | |
| A1. If you are living with someone working in a hospital milieu do you think they can contaminate you? | 735 (73.1) | 271(26.9) |
| A2. Are you willing to do a voluntary test for COVID 19? | 724 (72) | 282 (28) |
| A3. If you have another disease other than COVID 19, will you go to the hospital? | 718 (71.4) | 288 (28.6) |
| If No, why won’t you go to the hospital? | ||
| • Afraid of contamination | 214 (21.3) | / |
| • Misdiagnosis | 35 (3.5) | / |
| • Self-treatment | 13 (1.3) | / |
| • To avoid stigmatization | 9 (0.9) | |
| A4. Do you prefer to be confined in the house or hospital for your medical care when you are tested positive for COVID 19? | ||
| • House | 473 (47) | / |
| • Hospital | 378 (37.6) | / |
| •I don’t know | 155 (15.4) | / |
| Please explain the choice of staying at home | ||
| • Afraid of contamination | 166 (38.6) | / |
| • Better home care with family | 250 (58.1) | / |
| • Less costly | 4 (0.9) | / |
| • Stigmatization | 10 (2.3) | / |
| P1. Social distancing | 843 (83.8) | 163 (16.2) |
| P2. Washing hands and using sanitizers | 951 (94.5) | 55 (5.5) |
| P3.Total confinement | 201 (20) | 805 (80) |
| P4. Use of mask | 1006 (100) | 0 (0) |
| P5. Use of Traditional concoctions | 361 (35.9) | 645 (64.1) |
| P6. Taking chloroquine | 44 (4.4) | 962 (95.6) |
| P7. Eating citrus fruits such as lemon and taking Vitamin C tablets | 746 (74.6) | 260 (25.4) |
| P8. Taking paracetamol | 46 (4.6) | 960 (95.4) |
| P9. Taking Ibuprofen | 10 (1.0) | 996 (99) |
FFalse answers
Associations between background characters and Knowledge, attitudes regarding COVID 19.
| Variable | Knowledge Score (4–7) | Knowledge Score | (P-value) | Attitude Score (2–4) | Attitude Score (0–2) | (P-value) |
|---|---|---|---|---|---|---|
| Overall | ||||||
| • | 400 (84,7) | 72 (15,3) | 0,695 | 350 (74,2) | 122 (25,8) | <0.001 |
| • | 447 (83,7) | 87 (16,3) | 344 (64,4) | 190 (35,6) | ||
| Age | ||||||
| • | 20 (62,4) | 12 (37,5) | 0,003 | 14 (43,8) | 18 (56,3) | 0.028 |
| • | 293 (81,2) | 68 (18,8) | 257 (71,2) | 104 (28,8) | ||
| • | 326 (88,8) | 41 (11,2) | 250 (68,1) | 117 (31,9) | ||
| • | 119 (85,6) | 20 (14,4) | 96 (69,1) | 43 (30,9) | ||
| • | 89 (83,2) | 18 (16,8) | 77 (72) | 30 (28) | ||
| • | 91 (91,9) | 8 (8,1) | <0,001 | 79 (79,8) | 20 (20,2) | 0.003 |
| • | 163 (89,6) | 19 (10,4) | 112(61,5) | 70 (38,5) | ||
| • | 128 (90,8) | 13 (9,2) | 109 (77,3) | 32 (22,7) | ||
| • | 17 (100) | 0 (0) | 13(76,5) | 4 (23,5) | ||
| • | 207 (77,2) | 61 (22,8) | 183 (68,3) | 85 (31,7) | ||
| • | 108 (80) | 27 (20) | 97 (71,9) | 38 (28,1) | ||
| • | 133 (82,9) | 31 (17,1) | 114 (63) | 67 (37) | ||
| • | 168 (82) | 37 (18) | 0,146 | 129 (62,9) | 76 (37,1) | 0.007 |
| • | 227 (83,8) | 44 (16,2) | 177 (65,3) | 94 (34,7) | ||
| • | 90 (88,2) | 12 (11,8) | 82 (80,4) | 20 (19.6) | ||
| • | 225 (87,5) | 32 (12,5) | 189 (73,5) | 68 (26.5) | ||
| • | 137 (80,1) | 34 (19,9) | 117 (68.4) | 54 (31.6) | ||
| • | 538 (85,1) | 94 (14,9) | 0.009 | 439 (69.5) | 193 (30.5) | 0.023 |
| • | 130 (89) | 16 (11) | 91 (62.3) | 55 (37.7) | ||
| • | 70 (78,7) | 19 (21,3) | 56 (62.9) | 33 (37.1) | ||
| • | 109 (78,4) | 30 (21,6) | 108 (77.7) | 31 (22.3) |
*Statistically significant at p <0.05
Associations between background characters and practice regarding COVID 19.
| Variables | Practice Score | Practice Score (0–2) | (P-value) |
|---|---|---|---|
| Overall | |||
| • | 307 (65) | 165 (35) | |
| • | 305 (57,1) | 229 (42,9) | |
| • | 19 (59,4) | 13 (40,6) | |
| • | 203 (56,2) | 158 (43,8) | |
| • | 226 (61,6) | 141 (38,4) | |
| • | 91 (65,5) | 48 (34,5) | |
| • | 73 (68,2) | 34 (31,8) | |
| • | 62 (62,6) | 37 (37,4) | |
| • | 109 (59,9) | 73 (40,1) | |
| • | 86 (61) | 55 (39) | |
| • | 16 (94,1) | 1 (5,9) | |
| • | 159 (59,3) | 109 (40,7) | |
| • | 85 (63) | 50 (37) | |
| • | 95 (61,3) | 69 (38,7) | |
| • | 127 (62) | 78 (38) | |
| • | 144 (53,1) | 127 (46,9) | |
| • | 62 (60,8) | 40 (39,2) | |
| • | 164 (63,8) | 93 (36,2) | |
| • | 115 (67,3) | 56 (32,7) | |
| • | 368 (58,2) | 264 (41,8) | |
| • | 102 (69,9) | 44 (30,1) | |
| • | 55 (61,8) | 34 (38,2) | |
| • | 87 (62,6) | 52 (37,4) |
*Statistically significant at p <0.05
Factors associated with knowledge and practice towards COVID 19.
| Demographics/characteristics | Knowledge | P-value | Practice | P-value | Attitudes | P-value |
|---|---|---|---|---|---|---|
| • | 1 | 1 | 1 | |||
| • | 0,92 (0.66–1.30) | 0.65 | 0.72 (0.56–0.92) | 0.010 | 1.598(1.209–2.113) | 0.001 |
| Age | ||||||
| • | 1 | 1 | 1 | |||
| • | 2.58 (1.21–5.54) | 0.015 | 0.88 (0.42–1.83) | 0.73 | 3.366(1.563–7.249) | 0.002 |
| • | 4.77 (2.17–10.47) | <0,001 | 1.10 (0.53–2.29) | 0.81 | 2.746(1.190–6.339) | 0.018 |
| • | 3.57 (1.51–8.42) | 0.004 | 1.30 (0.59–2.85) | 0.52 | 2.712(1.108–6.637) | 0.029 |
| • | 2.97 (1.23–7.13) | 0.015 | 1.47 (0.65–3.32) | 0.36 | 3.347(1.310–8.553) | 0.012 |
| • | 1 | 1 | 1 | |||
| • | 0.75 (0.32–1.79) | 0.52 | 0.89 (0.54–1.47) | 0.65 | 0.418(0.234–0.748) | 0.003 |
| • | 0.87 (0.35–2017) | 0.76 | 0.93 (0.55–1.58) | 0.80 | 0.817 (0.430–1.551) | 0.536 |
| • | 0.30 (0.14–0.65) | 0.002 | 0.87 (0.54–1.40) | 0.57 | 0.614(0.166–2.273) | 0.465 |
| • | 0.35 (0.15–0.81) | 0.014 | 1.01 (0.59–1.73) | 0.96 | 0.622(0.331–1.166) | 0.138 |
| • | 0.42 (0.19–0.97) | 0.041 | 0.95 (0.57–1.57) | 0.83 | 0.385(0.212–0.698) | 0.002 |
| • | 1 | 1 | 1 | |||
| • | 1.42 (0.81–2.49) | 0.22 | 1.66 (1.13–2.45) | 0.010 | 0.715(0.480–1.064) | 0.098 |
| • | 0.64 (0.37–1.12) | 0.12 | 1.16 (0.74–1.83) | 0.52 | 0.689(0.425–1.118) | 0.132 |
| • | 0.63 (0.40–1.01) | 0.053 | 1.20 (0.82–1.75) | 0.34 | 1.418(0.906–2.220) | 0.127 |
*Statistically significant at p <0.05
Associations between age, gender with Comorbidity and symptoms of COVID 19.
| Gender | P-value | Age (years) | P-value | ||||
|---|---|---|---|---|---|---|---|
| Comorbidities | All patients | Female | Male | <30 | ≥30 | ||
| Hypertension | 47 (4.7) | 30 (5.6) | 17 (3.6) | 0.13 | 1 (0.3) | 46 (7.5) | <0.001 |
| Cancer | 2 (0.2) | 2 (0.4) | 0 (0.0) | 0.50 | 0 (0) | 2 (0.3) | 0.257 |
| Diabetes | 12 (1.2) | 8 (1.5) | 4 (0.8) | 0.39 | 1(0.3) | 11 (1.8) | 0.028 |
| Cardiovascular diseases | 7 (0.7) | 3 (0.6) | 4 (0.8) | 0.71 | 1 (0.3) | 6 (1.0) | 0.178 |
| Asthma | 19 (1.9) | 13 (2.4) | 6 (1.3) | 0.25 | 7 (1.8) | 12 (2.0) | 0.841 |
| Respiratory tract infection | 14 (1.4) | 8 (1.5) | 6 (1.3) | 0.75 | 3 (0.8) | 11 (1.8) | 0.27 |
| Common flu | 69 (6.9) | 37 (6.9) | 32 (6.8) | 0.93 | 26 (6.6) | 43 (7.0) | 0.81 |
| Allergic cough | 27 (2.7) | 19 (3.6) | 8 (1.7) | 0.068 | 7 (1.8) | 20 (3.3) | 0.16 |
| Tuberculosis | 4 (0.4) | 3 (0.6) | 1 (0.2) | 0.63 | 1 (0.3) | 3 (0.5) | 1.00 |
| Malaria | 247 (24.6) | 112 (21.0) | 135 (28.6) | 0.005 | 93 (23.7) | 154 (25.1) | 0.6 |
| Fever | 50 (5.0) | 26 (4.9) | 24 (5.1) | 0.87 | 21 (5.3) | 29 (4.7) | 0.063 |
| Dry cough/catarrah | 84 (8.3) | 38 (7.1) | 46 (9.7) | 0.13 | 27 (6.9) | 57 (9.3) | 0.174 |
| Headache | 132 (13.1) | 85 (15.9) | 47 (10.0) | 0.005 | 54 (13.7) | 78 (12.7) | 0.641 |
| Diarrhea | 9 (0.9) | 4 (0.7) | 5 (1.1) | 0.71 | 6 (1.5) | 3 (0.5) | 0.088 |
| Muscle pain | 60 (6.0) | 27 (5.1) | 33 (7.0) | 0.19 | 23 (5.9) | 37 (6.0) | 0.905 |
| Do not smell odor or taste | 22 (2.2) | 13 (2.4) | 9 (1.9) | 0.57 | 5 (1.3) | 17 (2.8) | 0.112 |
| Difficulty breathing | 25 (2.5) | 13 (2.4) | 12 (2.5) | 0.91 | 9 (2.3) | 16 (2.6) | 0.075 |
| Throat irritation | 65 (6.5) | 38 (7.1) | 27 (5.7) | 0.37 | 19 (4.8) | 46 (7.5) | 0.093 |
*Statistically significant at p <0.05
Associations between symptomatology and KAP.
| Symptomatology | Knowledge Score (4–7) | Knowledge | P-value | Attitude Score (0–2) | Attitude Score (2–4) | P-value | Practice Score | Practice Score | P-value |
|---|---|---|---|---|---|---|---|---|---|
| 628 (84.8) | 113 (15.2) | 0.419 | 516 (69.6) | 225 (30.4) | 0.456 | 454 (61.3) | 287 (38.7) | 0.638 | |
| 219 (82.6) | 46 (17.4) | 178 (67.2) | 87 (32.8) | 158 (59.6) | 107 (40.4) | ||||
| 203 (83.2) | 41 (16.8) | 0.416 | 162 (66.4) | 82 (33.6) | 0.359 | 145 (59.4) | 99 (40.6) | 0.824 | |
| 16 (76.2) | 5 (23.8) | 16 (76.2) | 5 (23.8) | 13 (61.9) | 8 (38.1) |
*Statistically significant at p <0.05
Fig 1Associations between the number of respondents with A) comorbidities, B) diseases with some common symptoms to COVID 19 and <4 symptoms or ≥ 4 symptoms of COVID 19.